Loading…
Minerva Neurosciences, Inc. is projected to decline to $3.84 by 2027, a -4% move from its current price of $3.98. NERV is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $3.82 | $3.98 | $4.14 | -0.03% |
| Aug 5 | $3.76 | $3.98 | $4.21 | -0.06% |
| Aug 6 | $3.71 | $3.98 | $4.26 | -0.09% |
| Aug 7 | $3.67 | $3.97 | $4.31 | -0.13% |
| Aug 8 | $3.63 | $3.97 | $4.35 | -0.16% |
| Aug 9 | $3.60 | $3.97 | $4.38 | -0.19% |
| Aug 10 | $3.57 | $3.97 | $4.42 | -0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.57 | $3.97 | $4.42 | -0.22% |
| Week 2 | $3.41 | $3.96 | $4.61 | -0.44% |
| Week 3 | $3.29 | $3.95 | $4.76 | -0.66% |
| Week 4 | $3.19 | $3.95 | $4.88 | -0.88% |
| Week 5 | $3.10 | $3.94 | $5.00 | -1.10% |
| Week 6 | $3.02 | $3.93 | $5.10 | -1.31% |
| Week 7 | $2.96 | $3.92 | $5.20 | -1.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of product candidates for central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
The company was incorporated in 2007 and is based in Burlington, Massachusetts. It operates in the Healthcare sector.
Minerva Neurosciences, Inc. trades under the symbol NERV. The stock is currently priced at $3.98 and has a market capitalization of $185.42M, ranking 3803 by size.
A major floor 26.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 39.4% above — a clean break opens room to run.
A major ceiling 84.7% above — clearing it would confirm fresh momentum.
Key NERV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NERV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.12 | Sell | $4.09 | Sell |
| MA 10 | $4.23 | Sell | $4.19 | Sell |
| MA 20 | $4.36 | Sell | $4.33 | Sell |
| MA 50 | $4.62 | Sell | $4.68 | Sell |
| MA 100 | $5.46 | Sell | $4.93 | Sell |
| MA 200 | $5.00 | Sell | $4.69 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.46 | Neutral |
| Stoch RSI (14) | 25.33 | Neutral |
| CCI (20) | -112.53 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -7.87 | Sell |
| Bollinger %B (20,2) | 0.15 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.46 | Sell |
| Awesome (5,34) | -0.36 | Sell |
| Ultimate (7,14,28) | 33.72 | Neutral |
| Momentum (10) | -0.29 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 4.00 | Sell |
| ADX (14) | 15.48 | Neutral |
| ATR (14) | 0.16 | Info |
The near-term technical picture is bearish. The RSI(14) is 40, and the stock trades with a 30-day range from $3.05 to $5.19. The current price sits near a support level of $3.98 and faces resistance near $5.55.
The 50-day simple moving average is $4.62, while the 200-day simple moving average is $5.00. These moving averages suggest limited upside momentum in the immediate term. The stock’s annualized volatility stands at 80%, indicating elevated swings.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.90 | $3.98 | $4.89 | 0% | Neutral | |
| $2.93 | $3.84 | $5.39 | -4% | Neutral | |
| $2.96 | $4.05 | $6.00 | +2% | Neutral | |
| $3.44 | $4.88 | $7.52 | +23% | Bullish | |
| $3.97 | $5.83 | $9.28 | +46% | Bullish | |
| $3.72 | $5.62 | $9.21 | +41% | Bullish | |
| $3.50 | $5.45 | $9.15 | +37% | Bullish | |
| $3.45 | $5.52 | $9.49 | +39% | Bullish | |
| $3.36 | $5.51 | $9.68 | +39% | Bullish | |
| $3.62 | $6.10 | $10.91 | +53% | Bullish | |
| $4.23 | $8.00 | $15.51 | +101% | Bullish | |
| $7.37 | $16.38 | $35.63 | +312% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.90 | $3.98 | $4.74 | +0.00% |
| September 2026 | $3.13 | $3.75 | $4.66 | -5.81% |
| October 2026 | $3.19 | $3.87 | $4.88 | +3.17% |
| November 2026 | $3.25 | $3.97 | $5.07 | +2.55% |
| December 2026 | $3.07 | $3.78 | $4.89 | -4.67% |
Click any year to see its month-by-month NERV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, NERV could reach as high as $4.89, with a base case around $3.98 and support toward $3.90 — roughly 0% from $3.98. Price action looks broadly range-bound.
Expect NERV to range from $2.93 to $5.39 through 2027. The $3.84 average target implies a -4% move from current prices. That is -4% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The NERV price prediction for 2028 points to an average of $4.05 (low $2.96, high $6.00) — a potential gain of +2% on today's $3.98. Price action looks broadly range-bound.
In 2029, NERV is projected to trade between $3.44 and $7.52, averaging $4.88 — a potential gain of +23% from today's $3.98. That is up +21% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Minerva Neurosciences, Inc.'s 2030 outlook centres on $5.83, within a $3.97 to $9.28 range. That is up +19% on the projected 2029 average. That marks a +46% change versus current levels. Momentum favours further upside here.
By 2031, NERV could reach as high as $9.21, with a base case around $5.62 and support toward $3.72 — roughly +41% from $3.98. Buyers look set to stay in control over this stretch.
Expect NERV to range from $3.50 to $9.15 through 2032. The $5.45 average target implies a +37% move from current prices. That is -3% versus the projected 2031 average. Momentum favours further upside here.
The NERV price prediction for 2033 points to an average of $5.52 (low $3.45, high $9.49) — a potential gain of +39% on today's $3.98. Buyers look set to stay in control over this stretch.
In 2034, NERV is projected to trade between $3.36 and $9.68, averaging $5.51 — a potential gain of +39% from today's $3.98. That is 0% versus the projected 2033 average. Momentum favours further upside here.
Minerva Neurosciences, Inc.'s 2035 outlook centres on $6.10, within a $3.62 to $10.91 range. That is up +11% on the projected 2034 average. That marks a +53% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, NERV could reach as high as $15.51, with a base case around $8.00 and support toward $4.23 — roughly +101% from $3.98. Momentum favours further upside here.
Expect NERV to range from $7.37 to $35.63 through 2050. The $16.38 average target implies a +312% move from current prices. That is up +105% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NERV today (≈ 251.256281 NERV) could be worth
$4,116.15
+$3,116.15 (+312%) by 2050 · US Dollar
Based on the average projected NERV price of $16.38 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NERVwould be worth at today's price.
$1,000 invested in NERV on Jul 31, 2025 (≈ 534.759357 NERV) would be worth
$2,128.34
+$1,128.34 (+112.8%) today · 2.13× · US Dollar
Based on a NERV entry price of $1.87 vs. today's $3.98.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.04 | $985.15 | -1.5% |
| 1 month ago | $5.15 | $772.82 | -22.7% |
| 3 months ago | $6.07 | $655.68 | -34.4% |
| 6 months ago | $4.68 | $850.43 | -15.0% |
| 1 year ago | $1.87 | $2,128.34 | +112.8% |
| All time (5.0y) ago | $13.68 | $290.94 | -70.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NERV forecast.
Our base-case forecast reaches $8.00 around 2050.
Implied market cap at $8.00: $372.71M
The multi-year forecast shows a bullish trajectory beginning in the later years, with 2029’s average price at $4.88 and a 22.7 search of ROI. The 2030 forecast places the average price at $5.83 with a 46.5 ROI, and 2031–2034 show continued upside with average prices around $5.6 and ROIs between 36.9 and 53.2. By 2035, the forecast projects an average of $6.10 with a 53.2 ROI.
The outlook strengthens into 2040, with an average price of $8.00 and a 101 ROI, and by 2050 an average of $16.38 with a 311.6 ROI. These numbers reflect a bullish longer-term view, but they are estimates and not guarantees. 2026–2028 are forecast as neutral to neutral/bullish transitions, leading to stronger upside in the later years.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $5.83 with an ROI of 46.5.
Forecasts indicate neutral sentiment in the near term (2026–2028) with a shift to bullish in later years; the 2030–2050 path shows rising average prices and higher ROIs, but these are estimates and not guarantees.
Yes. The forecast includes a max price of $10.91 in 2035 and $15.51 in 2040, with a 2050 max of $35.63, indicating that reaching $10 is within the provided range in the mid-term to long-term.
Current price is $3.98 and market cap is $185.42M.
For 2026, the min price is $3.90, the average is $3.98, and the max is $4.89, with a neutral sentiment.
Minerva Neurosciences, Inc. Community Discussion
0Share your Minerva Neurosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.